PCC Rokita SA

WSE:PCR Lagerbericht

Marktkapitalisierung: zł1.6b

PCC Rokita Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

PCC Rokita wird ein jährliches Gewinn- und Umsatzwachstum von 8% bzw. 4.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.8% betragen.

Wichtige Informationen

8.0%

Wachstumsrate der Gewinne

9.0%

EPS-Wachstumsrate

Chemicals Gewinnwachstum22.3%
Wachstumsrate der Einnahmen4.8%
Zukünftige Eigenkapitalrendite9.8%
Analystenabdeckung

Low

Zuletzt aktualisiert10 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?

May 30
Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Aug 24
Is PCC Rokita (WSE:PCR) Using Too Much Debt?

PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 29
PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year

Is PCC Rokita (WSE:PCR) A Risky Investment?

Jan 18
Is PCC Rokita (WSE:PCR) A Risky Investment?

PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23

Apr 16
PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23

Why We Like The Returns At PCC Rokita (WSE:PCR)

Mar 19
Why We Like The Returns At PCC Rokita (WSE:PCR)

What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?

Jan 25
What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?

We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

Sep 01
We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

Jun 14
Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

May 18
Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes

Apr 13
Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes

Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem

Mar 23
Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem

PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Mar 09
PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?

Feb 19
Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?

What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?

Feb 04
What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Jan 15
Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?

Dec 30
Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?

Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years

Dec 17
Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years

PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Dec 03
PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?

Nov 20
Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?

Gewinn- und Umsatzwachstumsprognosen

WSE:PCR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (PLN Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20262,3781891733763
12/31/20252,2491221272783
12/31/20241,95290983022
6/30/20242,048158212376N/A
3/31/20242,100144111310N/A
12/31/20232,388268296512N/A
9/30/20232,782473511736N/A
6/30/20233,072589623883N/A
3/31/20233,225692691941N/A
12/31/20223,143675563792N/A
9/30/20222,821569392621N/A
6/30/20222,560499383575N/A
3/31/20222,405472399553N/A
12/31/20212,203417380530N/A
9/30/20212,027294328468N/A
6/30/20211,827247267389N/A
3/31/20211,597171200342N/A
12/31/20201,476117195366N/A
9/30/20201,41473149340N/A
6/30/20201,46182136357N/A
3/31/20201,48272123355N/A
12/31/20191,4929377310N/A
9/30/20191,51314581316N/A
6/30/20191,50316055295N/A
3/31/20191,51220182356N/A
12/31/20181,49022741287N/A
9/30/20181,44524318254N/A
6/30/20181,378215-1220N/A
3/31/20181,345213N/A181N/A
12/31/20171,286182N/A204N/A
9/30/20171,234208N/A264N/A
6/30/20171,187213N/A264N/A
3/31/20171,129207N/A259N/A
12/31/20161,107203N/A263N/A
9/30/20161,084135N/A220N/A
6/30/20161,097131N/A187N/A
3/31/20161,077110N/A161N/A
12/31/20151,04985N/A149N/A
9/30/20151,05373N/A123N/A
6/30/20151,06262N/A130N/A
3/31/20151,08362N/A119N/A
12/31/20141,09371N/A165N/A
9/30/20141,06658N/A117N/A
6/30/20141,04148N/A96N/A
3/31/20141,08552N/A98N/A
12/31/20131,10158N/A104N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PCRDas prognostizierte Gewinnwachstum (8% pro Jahr) liegt über der Sparquote (3.9%).

Ertrag vs. Markt: PCRDie Erträge des Unternehmens (8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Polish (14.6% pro Jahr).

Hohe Wachstumserträge: PCRDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: PCRDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Polish (4.3% pro Jahr).

Hohe Wachstumseinnahmen: PCRDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PCRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.8%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y